BioCyto has created a strong and risk-diversified pipeline by adopting a ‘needs-led innovation’ approach to it drug delivery systems.
The pipeline consists of novel therapeutic nanocarriers generated from our in-house platform technologies.
Our platforms challenge current paradigms by nanoencapsulating therapeutics to augment their pharmacokinetics and pharmacodynamics for improved therapeutic index.
BioCyto is partnering / out-licensing its drug delivery systems to pharmaceutical companies for novel, already-marketed or clinically underperforming therapeutics.